IP-6
Research reviewed: Up until 03/2026
IP-6 (Inositol Hexaphosphate (IP6)) is a dietary supplement with 4 published peer-reviewed studies involving 340 participants, researched for Antioxidant & Cellular Health, Immune Support.
Evidence at a Glance
Strength is scored by study design, sample size, study type, and outcomes
Antioxidant & Cellular Health
ModerateImmune Support
ModerateResearch Visualised
Visual breakdown of the clinical data.
Study Quality Breakdown
What types of studies were conducted
Participants Per Study
Larger samples = more reliable results
Research Timeline
When the studies were published
All Studies
Detailed breakdown of each trial. Click to expand.
Antioxidant & Cellular Health
To review protection against cancer by dietary IP6 and inositol
Study Type
Review article
Purpose
To review protection against cancer by dietary IP6 and inositol
Dose
Various IP6 doses in diet/supplementation
Participants
Various study populations
Duration
Various
Results
IP6 recognized as strong antioxidant with ability to scavenge free radicals. Anti-cancer potential documented in laboratory studies.
How They Measured It
Literature review and synthesis
To review cellular and molecular activities of IP6 in disease prevention and therapy
Study Type
Review
Purpose
To review cellular and molecular activities of IP6 in disease prevention and therapy
Dose
Various (500-1000 mg/day typical)
Participants
Multiple study populations
Duration
Various
Results
IP6 demonstrates strong antioxidant properties, modulates immune function promoting NK cell activity and neutrophil regulation.
How They Measured It
Literature synthesis of mechanisms and clinical data
Immune Support
To evaluate beneficial effects of IP6 + Inositol in breast cancer patients receiving chemotherapy
Study Type
Prospective, randomized, pilot clinical study
Purpose
To evaluate beneficial effects of IP6 + Inositol in breast cancer patients receiving chemotherapy
Dose
IP6 + Inositol combination
Participants
14 invasive ductal breast cancer patients
Duration
During chemotherapy course
Results
Patients receiving chemotherapy with IP6 + Inositol did not have cytopenia or drop in leukocyte/platelet counts typically seen with chemo.
How They Measured It
Cytopenia, leukocyte and platelet counts, quality of life
To evaluate IP6 supplementation on serum uric acid levels in healthy volunteers
Study Type
Double-blind, randomized, crossover clinical study
Purpose
To evaluate IP6 supplementation on serum uric acid levels in healthy volunteers
Dose
600 mg IP6
Participants
Healthy volunteers
Duration
Crossover design
Results
IP6 supplementation resulted in decrease in serum uric acid levels compared to control group.
How They Measured It
Serum uric acid levels
Frequently Asked Questions
Common questions about IP-6 research
There are currently 5 peer-reviewed studies on IP-6 (Inositol Hexaphosphate (IP6)), involving 340 total participants. Research covers Antioxidant, Immune support, Cellular health. The overall evidence strength is rated as Moderate.
The evidence is currently rated as "Moderate Evidence". This rating is based on study design quality (randomisation, blinding, placebo controls), sample sizes, study types (4 human studies), and reported outcomes.
IP-6 has been researched for: Antioxidant, Immune support, Cellular health. Each area has its own body of evidence which you can explore in the study breakdowns above.
Yes, 4 out of 5 studies are human trials. Human trials carry more weight in our evidence scoring system.
Similar Supplements
Other supplements researched for similar health goals
